Sariah Kell - Concepedia

Author

Sariah Kell

Dynavax Technologies (United States)ORCID

Also Known As

Sariah A Kell, Sariah A. Kell, Sariah Kell

Publications

319

Citations

H-Index

Concepts

All Affiliations

Dynavax Technologies (United States)National Institutes of Health

About

Sariah Kell is an author at Dynavax Technologies (United States) specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	170
2	Immunology	3	3	170
3	Allergy	2	2	143
4	Engineering	1	1	27
5	Asthma	1	1	117

Sariah Kell

Publications

314

Citations

H-Index

Page 1

	Year	Citations
Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction Edith M. Hessel, Mabel Chu, Jennifer O. Lizcano, The Journal of Experimental Medicine InflammationAsthmaTh2 ResponseAllergyInflammatory Lung Disease	2005	117
Follicular Dendritic Cell Regulation of CXCR4-Mediated Germinal Center CD4 T Cell Migration Jacob D. Estes, Tyler C. Thacker, Denise L. Hampton, The Journal of Immunology	2004	75
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice John D. Campbell, Sariah Kell, Heather M. Kozy, Thorax	2014	40
First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated Sam Jackson, Albert F. Candia, Stephen Delaney, Clinical Pharmacology & Therapeutics	2017	29
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys Melissa A. Kachura, Colin L. Hickle, Sariah Kell, The Journal of Immunology EngineeringSucrose Polymer FicollImmunologyImmunotherapeuticsImmunotherapy	2015	27
Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells Sariah Kell, Melissa A. Kachura, Alex Renn, International Immunopharmacology Tlr9 Agonist Dv281Cancer ImmunosurveillancePreclinical DevelopmentAllergyImmunology	2018	26

Page 1